► In interstitial lung disease, there is a lack of validated biomarkers for disease staging, prediction of disease progression and drug responses, which impairs tailored patient management.
What does this study add?
► Our preclinical data suggest that targeted nuclear imaging of pathophysiological key players allows the visualisation of specific molecular processes of interstitial lung disease.
How might this impact on clinical practice or future developments?
► If transferred into clinics, where medical imaging is already part of the routine clinical work-up, the added information derived from specific diagnostic tools could represent the first step towards precision medicine in interstitial lung disease.
AbsTrACT
Objective To evaluate integrin αvβ3 (alpha-v-beta-3)-targeted and somatostatin receptor 2 (ssTR2)-targeted nuclear imaging for the visualisation of interstitial lung disease (ilD).
Methods The pulmonary expression of integrin αvβ3 and ssTR2 was analysed in patients with different forms of ilD as well as in bleomycin (BlM)-treated mice and respective controls using immunohistochemistry. single photon emission CT/CT (sPeCT/CT) was performed on days 3, 7 and 14 after BlM instillation using the integrin αvβ3-targeting 177 lu-DOTa-RGD and the ssTR2-targeting 177 lu-DOTa-nOC radiotracer. The specific pulmonary accumulation of the radiotracers over time was assessed by in vivo and ex vivo sPeCT/CT scans and by biodistribution studies. results expression of integrin αvβ3 and ssTR2 was substantially increased in human ilD regardless of the subtype. similarly, in lungs of BlM-challenged mice, but not of controls, both imaging targets were stagespecifically overexpressed. While integrin αvβ3 was most abundantly upregulated on day 7, the inflammatory stage of BlM-induced lung fibrosis, ssTR2 expression peaked on day 14, the established fibrotic stage. in agreement with the findings on tissue level, targeted nuclear imaging using sPeCT/CT specifically detected both imaging targets ex vivo and in vivo, and thus visualised different stages of experimental ilD. Conclusion Our preclinical proof-of-concept study suggests that specific visualisation of molecular processes in ilD by targeted nuclear imaging is feasible. if transferred into clinics, where imaging is considered an integral part of patients' management, the additional information derived from specific imaging tools could represent a first step towards precision medicine in ilD.
InTrOduCTIOn
Interstitial lung disease (ILD) is an umbrella term for a group of heterogeneous chronic parenchymal lung disorders with different aetiologies. The most prevalent subtypes include idiopathic pulmonary fibrosis (IPF) and ILD in the context of connective tissue diseases (CTD), particularly in association with systemic sclerosis (SSc). [1] [2] [3] Pulmonary fibrosis is the common end stage of ILD. 4 Histologically, the most common pattern of SSc-ILD is non-specific interstitial pneumonia (NSIP), whereas in IPF it is usual interstitial pneumonia (UIP). 2 4 In contrast to IPF, in SSc-ILD, this histological classification is not considered a reliable tool for outcome prediction. 2 5 However, the differences in cellularity, cell types and degree of lung remodelling in NSIP versus UIP point to differences in the underlying pathophysiology. 2 4 Currently, in ILD, no validated biomarkers for disease staging, prediction of disease progression and drug responses exist. [6] [7] [8] Given the highly heterogeneous nature of ILD, this largely leaves patient management at a trial-and-error stage, which stands in sharp contrast to the concept of precision medicine. 8 9 To address this unmet clinical need, we evaluated whether nuclear imaging as a specific ('targeted') and functional imaging modality could provide molecular information on the underlying pathophysiology 10 that could be used for substratification and tailored decision-making in ILD. Nuclear imaging methodologies include single photon emission CT (SPECT) and positron emission tomography (PET), which use radiolabelled, target-specific, molecular probes, that is, radiotracers for the real-time visualisation of pathophysiological processes. 10 For a proof-of-concept study showing that targeted nuclear imaging is feasible and has the potential for clinical application in ILD, we have selected two different molecules involved in the pathophysiology of ILD, that is, integrin alpha-v-beta-3 (αvβ3) and somatostatin receptor 2 (SSTR2), for which validated radiotracers are already available with good potential for short-term transferability into clinical application. 11 12 Compared with the current gold-standard diagnostic imaging methodologies, including high-resolution CT (HRCT) or 18 F-fluorodesoxyglucose (FDG)-PET/CT, integrin αvβ3-targeted and SSTR2-targeted nuclear imaging may have important advantages for the evaluation of patients with ILD. Although HRCT and 18 F-FDG-PET/CT are sensitive tools for the diagnosis of ILD, they are unspecific and cannot be used for the molecular subtyping of patients. Since they solely rely on the detection of changes in tissue morphology or in metabolic activity, respectively, they do not allow the discrimination of different pathophysiological stages of ILD, that is, inflammation, active fibrotic remodelling or established fibrosis, 13 14 which is paramount for informed treatment decisions and monitoring of therapeutic responses.
Alpha v integrins are key molecules in the pathogenesis of fibrosis in multiple organs due to their ability to activate matrixbound latent transforming growth factor beta (TGF-β), the prototypical profibrotic cytokine in tissue fibrosis. 15 16 Of particular importance in this regard is integrin αvβ3, which by activating TGF-β establishes an autocrine signalling loop in fibroblasts, thus driving myofibroblast differentiation. 16 17 Targeted imaging of integrin αvβ3 can be realised with arginine-glycine-aspartic acid (RGD) tripeptide-based radiotracers, which have already been validated (pre-)clinically. 11 18 19 SSTR2 is a G-protein-coupled receptor which is expressed on various cellular key players of lung remodelling, for example, epithelial cells, inflammatory cells 20 21 and potentially fibroblasts. 22 SSTR2 can be targeted with a series of peptides, that is, somatostatin analogues, which are already part of the routine management of neuroendocrine tumours. 12 23 Radiolabelled somatostatin analogues have recently been proposed for the visualisation of fibrotic changes in experimental 24 25 and human ILD. [26] [27] [28] [29] Herein, we evaluated the potential of molecular imaging of integrin αvβ3 and SSTR2 for the targeted visualisation of pathophysiological stages of ILD using the well-defined model of bleomycin (BLM)-induced lung fibrosis.
MeTHOds
A detailed description of the materials and methods, including information on patient characteristics, is provided in the online supplementary information.
resulTs expression of integrin αvβ3 and ssTr2 is increased in different types of Ild
To assess whether the expression of our molecular imaging targets is increased in human ILD, we performed immunohistochemistry for the β3 chain of integrin αvβ3 and SSTR2 on lung sections from patients with different types of ILD, including IPF and SSc-ILD, and other types of CTD-ILD (online supplementary table S1). Tissue specimens were obtained in the context of lung transplantation. The histopathological analysis revealed severely damaged lung architecture with massive accumulation of inflammatory infiltrates and extensive interstitial collagen deposition as assessed by H&E and CD45 or Picrosirius red and alpha-smooth muscle actin (αSMA) staining, respectively, which was consistent with end-stage ILD (figure 1A, online supplementary figure S1). In these highly inflamed and fibrotic lungs, expression of integrin αvβ3 and SSTR2 was significantly increased (~3-fold to 4-fold, p<0.05) compared with lungs from healthy subjects ( figure 1A-C) . Notably, this increase in expression was independent of the underlying aetiological subtype of ILD (figure 1A-C) and of other clinical characteristics (online supplementary figures S2 and S3). However, when comparing the expression of integrin αvβ3 and SSTR2 with respect to the histological subtypes of ILD, UIP and NSIP, we found a significantly higher expression of SSTR2 in the lungs with UIP pattern compared with those with NSIP pattern (p<0.01). In contrast, the expression of integrin αvβ3 did not differ between both histological subtypes (figure 1D,E).
expression of integrin αvβ3 and ssTr2 reflects different disease stages of experimental Ild
Given these promising results, we next assessed whether integrin αvβ3 and SSTR2 could also serve as surrogate markers for different pathophysiological stages in ILD. Therefore, we examined the time course of the pulmonary expression of integrin αvβ3 and SSTR2 in a representative mouse model of human ILD, the model of BLM-induced lung fibrosis.
A single intratracheal instillation of BLM (4 U/kg of body weight) in mice induced progressive lung remodelling with inflammation leading to established pulmonary fibrosis already 14 days after the BLM administration as assessed by tissue analysis (figure 2A,B) and CT scanning (online supplementary figure S4 ). Already on day 3, lungs from BLM-treated mice versus saline controls showed the presence of perivascular and peribronchial cellular infiltrates (figure 2A, H&E staining), which mainly consisted of CD45+ leucocytes (figure 2A, CD45 staining). In contrast, only limited fibrous thickening of the alveolar and bronchial walls (figure 2A, Picrosirius red staining) with no increase in αSMA expression (figure 2A, αSMA staining) was observed. With disease progression, the number of inflammatory infiltrates increased in BLM-treated lungs, peaked on day 7, and subsided thereafter (figure 2A, H&E and CD45 staining). In contrast, pulmonary fibrosis, characterised by extensive interstitial collagen deposition and increase of αSMA expression in the lung interstitium, reached its maximum on day 14 (figure 2A, Picrosirius red and αSMA staining). Although the progressing damage of lung architecture could also be depicted on CT (online supplementary figure S4), these morphological changes could not relay information on the underlying pathophysiology, that is, inflammation or fibrosis.
Notably, compared with saline-treated controls, the lungs of BLM-challenged mice showed significantly increased expression of integrin αvβ3 and SSTR2 at all time points. Interestingly, the expression of integrin αvβ3 was most abundant on day 7 and thus in the inflammatory stage of BLM-induced lung fibrosis, where inflammation is more dominant than fibrosis, with a median increase of 3.7 (Q1, Q3=2.9, 4.5) -fold (p<0.001) compared with control lungs (figure 2A-C). Although integrin expression decreased on day 14, it remained significantly upregulated in the lungs of BLM-treated mice (median (Q1, Q3) =2.4 (2.0, 4.2) -fold) (p<0.01). In contrast, the expression of SSTR2 gradually increased with the degree of lung remodelling and peaked on day 14, and thus in the fibrotic stage of this animal model, with a median of 3.8 (Q1, Q3=2.2, 4.3) -fold (p<0.01) increase compared with the lungs from saline-treated controls ( figure 2A-D) .
Given the rather conflicting reports of the pulmonary expression of integrin αvβ3 and SSTR2 in the literature, 20 24 we additionally analysed the cellular expression profiles of both targets in lung sections of BLM-treated mice and respective controls. Using immunofluorescent and/or immunohistochemical double Dunn's multiple correction or Mann-Whitney U test was applied (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). CTD, connective tissue disease; HC, healthy control; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NSIP, non-specific interstitial pneumonia; SSc, systemic sclerosis; SSTR2, somatostatin receptor 2; UIP, usual interstitial pneumonia. stainings with cell type-specific markers, we found both integrin αvβ3 and SSTR2 expressed on a broad range of inflammatory cell types, including leucocytes (CD45+, figure 3A,B) , macrophages (F4/80+, figure 3C,D) and T cells (CD3+, figure 3E,F) . Substantial expression of SSTR2 was found on pulmonary bronchial and alveolar epithelial cells (E-cadherin+), whereas expression of integrin αvβ3 was only rarely observed on epithelial cells in BLM-treated lungs and was absent on the epithelial cells in the lungs from the control mice ( figure 3G,H) . While integrin αvβ3 was strongly expressed on the pulmonary vasculature, including endothelial cells (von Willebrand factor (vWF)+, figure 3I ), SSTR2 expression was not detected on vWF+ endothelial cells despite being expressed in vascular structures ( figure 3J) .
Connective tissue diseases
The most interesting difference in the pulmonary expression pattern between integrin αvβ3 and SSTR2 was the presence of integrin αvβ3, but absence of SSTR2 on myofibroblasts (αSMA+, figure 4A,B) . The latter observation was in contrast to previous positive reports. 20 24 To confirm that the different expression of integrin αvβ3 and SSTR2 on murine lung fibroblasts also applies to human cells, we additionally analysed the mRNA and protein expression of both targets in normal human lung fibroblasts (NHLF) at basal conditions and after For E-I, data were expressed as mean±SD. For statistical analysis, one-way analysis of variance with Turkey's post-hoc test was performed (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). BLM, bleomycin; NHLFs, normal human lung fibroblasts; SSTR2, somatostatin receptor 2; TGF-β, transforming growth factor beta. differentiation into myofibroblasts on stimulation with TGF-β. Integrin αvβ3 was constitutively expressed in NHLF and showed a time-dependent increase after TGF-β-induced fibroblast activation at the mRNA and protein levels ( figure 4C,E,F) , similar to ACTA2/αSMA ( figure 4C,G,H) . In contrast, mRNA and protein levels of SSTR2 were not detectable in NHLF neither at basal conditions nor after stimulation with TGF-β (figure 4D/I and online supplementary figure S5 ), which so far has been a major matter of debate. 20 24 Thus, we could confirm similar expression patterns of our imaging targets on both murine and human lung fibroblasts.
detection of integrin αvβ3 with 177 lu-dOTA-rGd-sPeCT/CT visualises inflammatory stages of lung fibrosis
Having confirmed integrin αvβ3 and SSTR2 as potential imaging targets in ILD, targeted nuclear imaging was performed to confirm their suitability as surrogate imaging markers for
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pathophysiological processes in ILD. Since in the preclinical setting SPECT/CT often outperforms PET/CT with respect to image quality and resolution, SPECT/CT scans using the integrin αvβ3-targeting 177 Lu-DOTA-RGDand the SSTR2-targeting 177 Lu-DOTA-NOC were performed on days 3, 7 and 14 after the BLM instillation.
Consistent with the expression changes of integrin αvβ3 observed on tissue level, biodistribution studies (figure 5A and online supplementary tables S4 and S5) and ex vivo SPECT/ CT scans (figure 5B) performed 2 hours postinjection (p.i.) of 177 Lu-DOTA-RGD revealed a significant increase of tracer uptake and signal intensity in the lungs of BLM-treated mice versus control mice at all time points. The strongest tracer accumulation in BLM-treated lungs was observed on day 7 with a mean lung uptake of 0.65%±0.13% injected activity per lung (% IA/lung) compared with 0.19%±0.04% IA/lung in the respective control lungs (p<0.01). Specificity of the pulmonary accumulation of 177 Lu-DOTA-RGD was validated by receptor blockade with an unlabelled RGD peptide, which significantly reduced the pulmonary radioactivity amounts of 177 Lu-DOTA-RGD in BLM-treated mice to the levels detected in control animals. This was quantified by biodistribution studies and visualised by ex vivo SPECT/CT scans. The in vivo SPECT/CT imaging closely mirrored our ex vivo imaging results with the highest signal intensity observed on day 7 (figure 5C), the inflammation-dominant stage of BLM-induced lung fibrosis.
detection of ssTr2 with 177 lu-dOTA-nOC-sPeCT/CT visualises established lung fibrosis BLM-treated mice showed a steady increase of pulmonary accumulation of 177 Lu-DOTA-NOC as compared with saline-treated controls in biodistribution studies and ex vivo SPECT/CT scans that were performed 2 hours p.i. of 177 Lu-DOTA-NOC. This was in line with the expression changes of SSTR2 at the tissue level ( figure 5D,E) . The highest lung accumulation in BLM-challenged mice, and hence the highest imaging signal intensity, was observed on day 14, the peak of pulmonary fibrosis, with an accumulation of 1.62%±0.32% IA/lung vs 0.66%±0.09% IA/ lung in control lungs (p<0.0001). Due to already high basal pulmonary tracer accumulation observed in control animals, diseased lungs could only be reliably distinguished on day 14 (figure 5E and online supplementary tables S6 and S7). In vivo imaging mirrored the ex vivo findings and allowed the distinction of BLM-treated lungs from healthy lungs on day 14, the time point of established fibrosis, yet not at earlier, more inflammatory time points (figure 5F). The specificity of the pulmonary uptake of 177 Lu-DOTA-NOC, and thus of our imaging results, was confirmed by receptor blockade with unlabelled DOTA-NOC, which almost completely prevented the pulmonary accumulation of the radiotracer in BLM-treated mice ( figure 5D,E) .
dIsCussIOn
This study addressed a major unmet need in ILD, the lack of pathophysiologically relevant biomarkers allowing disease staging. Our comprehensive approach integrating tissue-derived human and murine ex vivo and in vivo (imaging) data extends previously published nuclear imaging studies in ILD, where molecular analyses on tissue levels have largely not been performed. [26] [27] [28] [29] One of the first key findings of our study was that the expression of our imaging targets did not differ between different aetiologies of ILD comprising IPF and CTD-associated ILD. With pulmonary fibrosis as the common end stage, increasing data support the importance of dysregulated wound-healing mechanisms for both entities. 2 30 Furthermore, in contrast to previous assumptions regarding the non-inflammatory pathogenesis of IPF, 5 31 lately, the potential pathogenic role of immune cells in the development and progression of IPF has been re-evaluated. 32 33 Thus, a molecular-based rather than a clinical/histological-driven classification as the basis for substratification of patients with ILD might open novel perspectives.
Consistent with the expression of integrin αvβ3 on (activated) fibroblasts in addition to immune cells, we identified integrin αvβ3 as a valuable diagnostic tool for inflammation-dominant fibrotic stages of ILD and demonstrated that molecular-targeted SPECT/CT imaging using a radiolabelled RGD peptide can act as a surrogate marker for integrin αvβ3 expression. However, given the central roles of integrins in the pathogenesis of ILD, other integrins might also be attractive as imaging targets. 11 34 Of particular interest is, for example, integrin αvβ6, which is expressed on epithelial cells, and overexpressed in wound healing and IPF. [35] [36] [37] [38] Preclinical imaging studies in BLM-induced lung fibrosis confirmed its potential, 34 and results from phase I clinical trials on imaging in IPF are soon to be awaited ( www. clinicaltrials. gov; NCT03183570 and NCT02052297). Besides showing great promise as novel diagnostic tools, integrins represent potential therapeutic targets in ILD. Evidence from preclinical models of organ fibrosis demonstrated beneficial antifibrotic effects for the inhibition of integrin signalling. 15 16 37 38 In oncology, numerous selective integrin inhibitors are currently being tested in clinical trials, [39] [40] [41] since many tumours overexpress integrin αvβ3, αvβ5 and/or αvβ6. 42 Given the promising data from preclinical fibrosis models, these approaches could be easily applied for studies in ILD.
In contrast to integrin αvβ3, our data suggest that SSTR2 may serve as a diagnostic tool for established lung fibrosis and thus ILD severity. Targeted SPECT/CT using the radiolabelled somatostatin analogue DOTA-NOC revealed a steady increase in signal intensity over time mirroring the degree of tissue remodelling, thereby reaching its peak on day 14, the time point of established fibrosis. This is also in line with the increased expression of SSTR2 in patients with ILD with UIP pattern, where lung remodelling is more severe than in the NSIP subtype and where epithelial cells are supposed to be the central drivers of pulmonary fibrosis. 30 Further support comes from preliminary nuclear imaging studies targeting SSTR2 with different radiolabelled somatostatin analogues in patients with ILD, which showed lower signal intensity in patients with NSIP/SSc-ILD compared with patients with IPF/UIP. [27] [28] [29] Like integrin αvβ3, SSTR2 has diagnostic and therapeutic potential. Several preclinical studies using different somatostatin analogues showed beneficial effects on organ fibrosis. 24 43 44 Although increasing data suggest SSTR2 for imaging and possibly treatment of ILD, it should be pointed out that the precise pathophysiological role of SSTR2 in ILD has yet to be elucidated. Of note, SSTR-targeted (radio)pharmaceuticals are not specific for SSTR2, but also bind to other somatostatin receptors with similar affinity, including SSTR3 and SSTR5. 20 45 46 Herein, we demonstrated on several experimental levels that neither murine nor human lung fibroblasts express SSTR2. In previous studies which had reported on the SSTR2 expression on fibroblasts, fibroblasts from other sites of origin (eg, skin, retro-orbital space or liver) [47] [48] [49] and/or from embryonic stage were assessed. 50 This, and the fact that SSTR2 is expressed in two protein variants, generated by alternative splicing, 51 might well account for the observed differences. Consequently, in (experimental) ILD, it seems likely that both radiotracer 
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uptake and antifibrotic effects of SSTR analogues can largely be attributed to inflammation and epithelial cell damage. 24 27 However, further studies are needed to assess whether pulmonary fibroblasts express SSTR3 and SSTR5 and might therefore be directly targeted by somatostatin analogues.
Additional profibrotic molecules which could be of interest for targeted nuclear imaging include extracellular matrix proteins, for example, collagens, fibronectin or fibroblast activation protein. 3 52 However, in contrast to our selected imaging targets, radiotracers for these molecules have so far only been validated in animal models 53 54 or in human non-ILD conditions. [55] [56] [57] Furthermore, imaging tools that exclusively detect fibrotic changes will probably not reflect pathophysiological changes caused by immune and/or epithelial cells and consequently may provide a less complete picture of the overall disease process. However, fibrosis markers could be valuable for monitoring therapeutic responses to fibroblast-targeting therapies in defined subcohorts of patients with ILD. The detection of ILD in the context of multiorgan inflammation and fibrosis might represent a challenge. Thus, the performance of our radiotracers should ideally have been evaluated in a second, multisystemic animal model, which better reflects the human situation in CTD-ILD. However, the available literature on PET/CT imaging provides substantial evidence that even in patients with CTD with multiorgan involvement, ILD can reliably be diagnosed. [58] [59] [60] [61] [62] [63] [64] [65] In conclusion, both integrin αvβ3 and SSTR2 are intriguing candidates for the visualisation of specific molecular processes in ILD. Since SSTR2 targeting 68 Ga-DOTA-NOC PET/CT is already available in clinical routine for the diagnosis of neuroendocrine tumours and several RGD-targeted PET tracers such as 68 Ga-NOTA-RGD are in clinical trials, 11 18 19 the findings of our study could be easily and rapidly transferred into clinical application for proof-of-concept studies in patients with ILD. This could represent the first step towards molecular patients' stratification and thus precision medicine approaches in ILD.
